Commentary: Impact of pexelizumab, an anti-C5 complement antibody, on total mortality and adverse cardiovascular outcomes in cardiac surgical patients undergoing cardiopulmonary bypass. The Annals of Thoracic Surgery, Volume 77, Issue 3, March 2004, Pages 942-949: Invited commentary

Commentary: Impact of pexelizumab, an anti-C5 complement antibody, on total mortality and adverse cardiovascular outcomes in cardiac surgical patients undergoing cardiopulmonary bypass. The Annals of Thoracic Surgery, Volume 77, Issue 3, March 2004, Pages 942-949: Invited commentary

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The Annals of thoracic surgery 2004, Vol.77 (3), p.949
1. Verfasser: Svedjeholm, R.
Format: Artikel
Sprache:eng
Schlagworte:
NATURAL SCIENCES
NATURVETENSKAP
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:
ISSN:1552-6259
0003-4975
DOI:10.1016/j.athoracsur.2003.10.023